We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where UroGen Pharma Ltd. (NASDAQ:URGN) stands against other best small-cap growth stocks to buy now.

Are Small-Cap Stocks Poised for Growth?

On November 4, 2024, Nick Sheridan, Portfolio Manager at Janus Henderson released a report on small-cap stocks exploring how these stocks offer unique growth and diversification opportunities. Sheridan highlighted that maintaining visibility amidst the dominance of mega-cap tech stocks has been a challenge for small-cap stocks. Historically, small caps have been overshadowed by larger companies, which have captured investor attention with themes like artificial intelligence and have seen ever-higher multiples as a result. However, Sheridan notes that this is not a new phenomenon. Small caps have consistently delivered higher earnings growth than large caps over time, therefore, making them an attractive option for investors seeking growth and diversification.

READ NEXT: 10 Hot Penny Stocks to Buy Now and 10 Hot New Stocks to Buy Now.

In recent years, mega-cap tech stocks have been the driving force behind the stock market, but cracks have begun to appear in their performance, leading investors to seek value elsewhere. On the other hand, as interest rates are expected to decrease, small caps are poised to benefit, as they historically perform well in such environments. Sheridan highlighted that the key to small-cap outperformance lies in their ability to grow earnings more rapidly than large-caps, which struggle to achieve significant growth due to their size and market penetration. Small caps can expand into new markets, acquire new clients, or broaden their product range more easily than larger companies.

Moreover, small caps also serve as a diversification tool for investors. They often operate in different sectors, such as industrials and materials, and are more focused on local markets, providing exposure to structural trends like de-globalization. Sheridan noted that despite their potential, small caps remain under-researched and undervalued, offering opportunities for investors willing to conduct thorough research to identify quality growth companies. In addition, the persistent merger and acquisition activity, where larger companies acquire smaller ones at a premium, further supports the case for investing in small caps. According to Bloomberg, 95% of M&A deals involve a small-cap target, thereby adding substance to Sheridan’s argument. Lastly, Sheridan concluded by mentioning that small caps remain an undiscovered territory for many investors, requiring more effort to uncover hidden gems but offering substantial rewards for those who do.

Our Methodology

To curate the list of the 10 best small-cap growth stocks to buy now, we used the Finviz stock screener, Seeking Alpha, and Insider Monkey’s Q4 2024 hedge funds database. Using the screener we compiled an initial list of small-cap growth stocks. Next, we used Seeking Alpha to shortlist stocks that have grown more than 30% during the past 3 years. Lastly, we ranked the stocks in ascending order based on the number of hedge fund holders sourced from Insider Monkey’s database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

UroGen Pharma Ltd. (NASDAQ:URGN)

3-Year Sales Growth: 30.91%

Number of Hedge Fund Holders: 30

UroGen Pharma Ltd. (NASDAQ:URGN) focuses on developing innovative treatments for urothelial and specialty cancers, as well as urologic diseases. The company uses a proprietary technology called RTGel, which is a reverse-thermal hydrogel that helps drugs stay in the body longer, making them more effective. Its main products include Jelmyto (MitoGel or UGN-101) and VesiGel (UGN-102). These treatments aim to ablate tumors without surgery, offering patients more effective and less invasive options for managing their conditions.

The company is making significant progress with UGN-102, a groundbreaking therapy for low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has accepted a New Drug Application for UGN-102, with a Prescription Drug User Fee Act target date of June 13, 2025. This is a pivotal step toward potential approval, which could make UGN-102 the first FDA-approved treatment for LG-IR-NMIBC. The market for UGN-102 is substantial, with over 80,000 addressable patients annually in the US, representing a potential market size of over $5 billion.

On February 19, Ladenburg kept a Buy rating on the stock with a price target of $31. The firm noted that they see a smooth path for the approval of  UGN-102, which will be a positive step for UroGen Pharma Ltd. (NASDAQ:URGN). It is one of the best small-cap growth stocks to buy now.

Overall, URGN ranks 2nd on our list of  best small-cap growth stocks to buy now. While we acknowledge the potential of URGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than URGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.